Resolution of Tardive Dyskinesia Following a Switch from Long-Acting Injectable Risperidone to Aripiprazole
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tardive dyskinesia (TD) is a serious neurological side effect of antipsychotics. Dopaminergic hypersensitivity mediated by the upregulationof the D2 receptor with prolonged dopamine blockade is thought to play a key role in the development of neurolepticinducedTD. Aripiprazole, a partial dopamine agonist, causes little dopamine up-regulation; therefore, it may be associated witha lower risk of TD. We present a literature review and a case in which a schizophrenic patient developed TD while using longactinginjectable risperidone, which was completely resolved following a switch to aripiprazole. The resolution of TD in this patientwas sustained during 22 months of follow-up treatment with aripiprazole. Aripiprazole may be an effective treatment option forpatients who suffer from neuroleptic-induced TD.
Abstract
Tardive dyskinesia (TD) is a serious neurological side effect of antipsychotics. Dopaminergic hypersensitivity mediated by the upregulationof the D2 receptor with prolonged dopamine blockade is thought to play a key role in the development of neurolepticinducedTD. Aripiprazole, a partial dopamine agonist, causes little dopamine up-regulation; therefore, it may be associated witha lower risk of TD. We present a literature review and a case in which a schizophrenic patient developed TD while using longactinginjectable risperidone, which was completely resolved following a switch to aripiprazole. The resolution of TD in this patientwas sustained during 22 months of follow-up treatment with aripiprazole. Aripiprazole may be an effective treatment option forpatients who suffer from neuroleptic-induced TD.
참고문헌 (20)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th ed" (1994), American Psychiatric Press Inc
- Silvestri S, "Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study", Psychopharmacology, 152, pp.174~180 (2000)
- Nasrallah HA, "Focus on lower risk of tardive dyskinesia with atypical antipsychotics", Ann Clin Psychiatry, 18, pp.57~62 (2006)
- Stahl SM, "Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors", J Clin Psychiatry, 62, pp.841~842 (2001)
- Miller del D, "Comparative ssessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis", J Clin Psychiatry, 68, pp.1901~1906 (2007)
- Duggal HS, "Aripiprazole-induced improvement in tardive dyskinesia", Can J Psychiatry, 48, pp.771~772 (2003)
- Witschy JK, "Improvement in tardive dyskinesia with aripiprazole use", Can J Psychiatry, 50, pp.188~ (2005)
- Grant MJ, "Possible improvement of neurolepticassociated tardive dyskinesia during treatment with aripiprazole", Ann Pharmacother, 39, pp.1953~ (2005)
- Sharma A, "Resolution of ziprasidone- related tardive dyskinesia with a switch to aripiprazole", Prim Care Companion J Clin Psychiatry, 7, pp.36~ (2005)
- Lykouras L, "Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsy chotics", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1535~1536 (2007)
- Rizos E, "Tardive dyskinesia in a patient treated with quetiapine", World J Biol Psychiatry (2008)
- Kantrowitz JT, "Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot", J Clin Psychopharmacol, 27, pp.525~526 (2007)
- Guy W, "ECDEU Assessment Manual for Psychopharmacology", pp.534~537 (1976), US Department of Health, Education, and Welfare
- Eerdekens M, "Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia", Schizophr Res, 70, pp.91~100 (2004)
- Gharabawi GM, "An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study", Schizophr Res, 77, pp.129~139 (2005)
- Inoue A, "Aripiprazole, a novel antipsychotic drug, inhibits quinpiroleevoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum", Eur J Pharmacol, 321, pp.105~111 (1997)
- Zhang XY, "The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial", J Clin Psychopharmacol, 24, pp.83~86 (2004)
- Soares KV, "Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;CD000209", ~ (2001)
- Maytal G, "Aripiprazole-related tardive dyskinesia", CNS Spectr, 11, pp.435~439 (2006)
- Zaidi SH,, "Aripiprazole is associated with early onset of tardive dyskinesia like presentation in a patient with ABI and psychosis.", Brain Inj, 22, pp.99~102 (2008)